Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
PainChek LtdTelephone
61.8.9388.8290
Address
Suite 401 35 Lime Street Sydney, New South Wales (NSW) 2000
Description
N/A
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.03 - 0.05
Trade Value (12mth)
AU$8,837.00
1 week
3.23%
1 month
0%
YTD
-11.11%
1 year
-36%
All time high
0.44
EPS 3 yr Growth
5.60%
EBITDA Margin
-356.30%
Operating Cashflow
-$7m
Free Cash Flow Return
-727.90%
ROIC
-848.40%
Interest Coverage
N/A
Quick Ratio
1.40
Shares on Issue (Fully Dilluted)
1528m
HALO Sector
Technology
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
04 October 24 |
Notification of cessation of securities - PCK
×
Notification of cessation of securities - PCK |
04 October 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
02 October 24 |
PainChek Adult app FDA De Novo submission update
×
PainChek Adult app FDA De Novo submission update |
02 October 24 |
Application for quotation of securities - PCK
×
Application for quotation of securities - PCK |
30 September 24 |
Annual Report to shareholders
×
Annual Report to shareholders |
30 September 24 |
Corporate Governance Statement & Appendix 4G 2024
×
Corporate Governance Statement & Appendix 4G 2024 |
27 September 24 |
Notification of cessation of securities - PCK
×
Notification of cessation of securities - PCK |
30 August 24 |
Preliminary Final Report
×
Preliminary Final Report |
02 August 24 |
Notification of cessation of securities - PCK
×
Notification of cessation of securities - PCK |
30 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
30 July 24 |
Investor Webinar Presentation
×
Investor Webinar Presentation |
26 July 24 |
Quarterly update webinar - Tuesday, 30 July 2024
×
Quarterly update webinar - Tuesday, 30 July 2024 |
28 May 24 |
PainChek receives European patent for pain assessment tech
×
PainChek receives European patent for pain assessment tech |
30 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
23 April 24 |
PainChek receives $1,210,000 R&D Tax Incentive Refund
×
PainChek receives $1,210,000 R&D Tax Incentive Refund |
20 March 24 |
Application for quotation of securities - PCK
×
Application for quotation of securities - PCK |
20 March 24 |
Notice under Section 708A(5)(e) of the Corporation Act 2001
×
Notice under Section 708A(5)(e) of the Corporation Act 2001 |
18 March 24 |
PCK to present at NWR Virtual Healthcare Conference
×
PCK to present at NWR Virtual Healthcare Conference |
15 March 24 |
Change of Director's Interest Notices x5
×
Change of Director's Interest Notices x5 |
14 March 24 |
PainChek completes A$5m capital raise
×
PainChek completes A$5m capital raise |
14 March 24 |
Update - Proposed issue of securities - PCK
×
Update - Proposed issue of securities - PCK |
14 March 24 |
PainChek UK partnership with Nourish Care
×
PainChek UK partnership with Nourish Care |
12 March 24 |
Trading Halt
×
Trading Halt |
11 March 24 |
Completion of Security Purchase Plan
×
Completion of Security Purchase Plan |
11 March 24 |
Application for quotation of securities - PCK
×
Application for quotation of securities - PCK |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.